Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Wyatt McDonnell, Ph.D., cofounder and CEO at Infinimmune, talks about how single-cell biology and computational rigor led to the formation of Infinimmune, and a new way to discover human-derived antibody drugs. Wyatt explains Infinimmune's 'discovered in humans' antibody discovery platform, how the company was launched and initially funded, and how Infinimmune landed a Merck collaboration worth up to $838 million. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn : https://www.linkedin.com/in/bencomer/